Abstract
AbstractObesity is a widespread health issue worldwide. Therefore, evaluating existing pharmaceuticals and developing new effective strategies to mitigate the problem is essential. Although literature reviews of a broad range of interventions for managing obesity exist, a recent evaluation of the efficacy of orlistat is lacking. This meta-analysis aims to quantify the efficacy of orlistat on body mass index (BMI) and the impact of age, dose, duration, and comorbidities. A literature search of orlistat on PubMed was carried out, and 177 placebo-controlled randomized clinical trials published in the last twenty years were identified. Sixteen studies that met the inclusion criteria were selected for further analysis. Two investigators independently extracted data from the clinical reports using a predefined protocol. We conducted a meta-analysis using random and mixed effects models with different moderators. We found that, on aggregate, the orlistat group reduced their BMI by 0.72 kg/m2(P< 0.05) compared to the placebo group. In addition, a longer duration of intervention led to a greater decrease in BMI. Moreover, patients with comorbidities experienced a smaller change in BMI. In conclusion, the evidence suggests that orlistat moderately reduces BMI in obese subjects. The effect of lifestyle modifications, side effects, and drug interactions should be assessed in future studies.
Publisher
Cold Spring Harbor Laboratory
Reference32 articles.
1. Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects’;Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association,2007
2. Comparative effects of sibutramine and orlistat on weight loss, glucose metabolism and leptin levels in non-diabetic obese patients: A prospective study’;Indian journal of endocrinology and metabolism,2012
3. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study’;The Lancet,2009
4. Orlistat increases serum paraoxonase activity in obese patients’;Nutrition, metabolism, and cardiovascular diseases: NMCD,2007
5. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension